Reyvow

Product manufactured by Eli Lilly And Company

Application Nr Approved Date Route Status External Links
NDA211280 None Oral None Google , Wikipedia , PubMed , DailyMed , Raw OpenFDA , ECHA , ToxNet , JECFA , FAO , 21 CFR

Indications and Purposes

1 Indications And Usage Reyvow™ Is Indicated For The Acute Treatment Of Migraine With Or Without Aura In Adults. Reyvow™ Is A Serotonin (5-Ht) 1f Receptor Agonist Indicated For The Acute Treatment Of Migraine With Or Without Aura In Adults. ( 1 ) Limitations Of Use Reyvow Is Not Indicated For The Preventive Treatment Of Migraine. ( 1 ) Limitations Of Use Reyvow Is Not Indicated For The Preventive Treatment Of Migraine.

All Formulated Excipients (0 Total)

None

Active Ingredients ( 1 Total)

Name Structure ZINC ID(s)
1. Lasmiditan LASMIDITAN ZINC3818355

Comments